Abstract
The novel colorectal neoplasia differentially expressed lncRNA (CRNDE) has been discovered in many solid tumors. We conducted this systematic review and meta-analysis to illuminate the function of CRNDE in cancer. Published articles were identified by electronic search of PubMed, EMBASE, and MEDLINE using the keywords "cancer or carcinoma or neoplasm or tumor" and "long noncoding RNA CRNDE or noncoding RNA CRNED or CRNDE". Hazard ratios (HRs), standard errors (SEs) and their corresponding 95% confidence intervals (CIs) were estimated from study survival curves. Odds ratios (ORs) with 95% CIs were estimated in order to evaluate the correlation between CRNDE expression level and cancer patient clinical outcome. Herein, 13 of the 49 identified studies completely fulfilled inclusive criteria for this systemic review. The results are as follows: the pooled HR of high expression versus low expression of CRNDE was 1.64 with a 95% CI of [1.44, 1.87]; the pooled OR of high CRNDE expression in early TNM stages versus late TNM stages was 0.35 with a 95% CI of [0.26, 0.47]; the pooled OR of high CRNDE expression in positive lymph node metastasis versus negative lymph node metastasis was 3.62 with a 95% CI of [1.99, 6.58]; the pooled OR of high CRNDE expression in tumor size larger than 5 cm versus tumor size smaller than 5 cm was 2.99 with a 95% CI of [1.13, 7.93]. For colorectal cancer studies, the pooled OR of high CRNDE expression in colon tumor versus rectal tumor was 1.18 with a 95% CI of [0.64, 2.18], the pooled OR of high CRNDE expression among T1 and T2 versus T3 and T4 was 0.91 with a 95% CI of [0.57, 1.46], and the pooled OR of high CRNDE expression in colorectal cancer patients without distant metastasis versus patients with distant metastasis was 0.48 with a 95% CI of [0.21, 1.10]. No obvious publication bias was observed in any study in this meta-analysis. CRNDE was confirmed an oncogene, and its up-regulated expression significantly correlated with poor prognosis and advanced tumor progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
